{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T19:53:52Z","timestamp":1778010832014,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2015,11,13]],"date-time":"2015-11-13T00:00:00Z","timestamp":1447372800000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2015,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Musculoskeletal symptoms are the most common extra\u2010intestinal manifestation associated with inflammatory bowel disease (<jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content>). Spondyloarthritis (<jats:styled-content style=\"fixed-case\">SpA<\/jats:styled-content>) is an umbrella term applied to a group of rheumatic diseases with some features in common and others distinct from other inflammatory arthritides.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To determine self\u2010reported prevalence of <jats:styled-content style=\"fixed-case\">SpA<\/jats:styled-content> associated musculoskeletal manifestations in an <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> cohort on tumour necrosis factor (<jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>) inhibitors using a questionnaire incorporating Assessment of SpondyloArthritis International Society (<jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content>) criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> patients on <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> inhibitors attending a single <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> centre (<jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>ay\u2013<jats:styled-content style=\"fixed-case\">S<\/jats:styled-content>eptember 2011) were asked to complete a <jats:styled-content style=\"fixed-case\">SpA<\/jats:styled-content> questionnaire. Data collected included <jats:styled-content style=\"fixed-case\">SpA<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> variables, demographics, concurrent medications, co\u2010morbidities and autoimmune serology.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The 140\u2010patient cohort included 96 suffering from Crohn disease and 44 from ulcerative colitis. The mean age of disease onset was 29.3 years and 45% were men. Concurrent or past history of inflammatory back pain was reported by 29% subjects. Using the imaging and clinical arms of the <jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content> criteria, 30% and 14% subjects respectively had axial <jats:styled-content style=\"fixed-case\">SpA<\/jats:styled-content>. Arthritis was reported by 34%, enthesitis 17%, dactylitis 4%, uveitis 6%, psoriasis 6% and a family history of <jats:styled-content style=\"fixed-case\">SpA<\/jats:styled-content> in 39%. Peripheral <jats:styled-content style=\"fixed-case\">SpA<\/jats:styled-content> was present in 41% by the <jats:styled-content style=\"fixed-case\">ASAS<\/jats:styled-content> criteria. There were no differences in these frequencies between Crohn disease and ulcerative colitis. A positive antinuclear antibodies (&gt;1:80) was found in 19% before commencement of <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> inhibitor therapy and increased to 78% on therapy. Clinical drug\u2010induced lupus erythematosus was uncommon (4%) and was characterised by new clinical signs and symptoms, including arthralgia, rash with elevated dsDNA titres and positive antinuclear antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Inflammatory bowel disease patients on <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content> inhibitors frequently reported musculoskeletal manifestations. Increased recognition of <jats:styled-content style=\"fixed-case\">SpA<\/jats:styled-content> occurred with use of an <jats:styled-content style=\"fixed-case\">SpA<\/jats:styled-content> self\u2010reported questionnaire in <jats:styled-content style=\"fixed-case\">IBD<\/jats:styled-content> patients: this could alter management and improve patient outcomes. Clinical drug\u2010induced lupus erythematosus was uncommon.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.12891","type":"journal-article","created":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T07:33:51Z","timestamp":1441352031000},"page":"1154-1160","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Spondyloarthropathy in inflammatory bowel disease patients on <scp>TNF<\/scp> inhibitors"],"prefix":"10.1111","volume":"45","author":[{"given":"K.","family":"Subramaniam","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology Unit Canberra Hospital  Canberra Australian Capital Territory Australia"},{"name":"Australian National University Medical School  Canberra Australian Capital Territory Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Tymms","sequence":"additional","affiliation":[{"name":"Rheumatology Department Canberra Hospital  Canberra Australian Capital Territory Australia"},{"name":"Australian National University Medical School  Canberra Australian Capital Territory Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Shadbolt","sequence":"additional","affiliation":[{"name":"Centre for Advances in Epidemiology and Information Technology Canberra Hospital  Canberra Australian Capital Territory Australia"},{"name":"Australian National University Medical School  Canberra Australian Capital Territory Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Pavli","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit Canberra Hospital  Canberra Australian Capital Territory Australia"},{"name":"Australian National University Medical School  Canberra Australian Capital Territory Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,11,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1080\/003655201317097173"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20942"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2009.01.013"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.133645"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2217\/ijr.12.61"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.101501"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780270401"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2012.09.003"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/03009740600904243"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.141598"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121029"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ibd.20029"},{"issue":"3","key":"e_1_2_10_15_1","first-page":"127","article-title":"The anti IL\u201017 A monoclonal antibody secukinumab (AIN457) showed good safety and efficacy in the treatment of active ankylosing spondylitis","volume":"70","author":"Baeten D","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_10_16_1","first-page":"S1080","article-title":"Ustekinumab in active psoriatic arthritis including patients previously treated with anti\u2010TNF agents: results of a phase 3, multicentre, double\u2010blind placebo\u2010controlled study","volume":"64","author":"Ritchlin C","year":"2012","journal-title":"Arthritis Rheum"},{"key":"e_1_2_10_17_1","first-page":"4172","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, 1 patient with psoriatic arthritis: results of a phase 3 randomised, controlled trial","volume":"64","author":"Kavanaugh A","year":"2012","journal-title":"Arthritis Rheum"},{"key":"e_1_2_10_18_1","first-page":"5","article-title":"The challenge of early diagnosis in ankylosing spondylitis","volume":"34","author":"O'Shea F","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1977.03270510035017"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0797-5"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s100670070003"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03868.x"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12680"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199607000-00009"},{"key":"e_1_2_10_25_1","first-page":"2860","article-title":"Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association","volume":"27","author":"Vlam K","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2010.343"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2008.12.008"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.12891","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.12891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:51:10Z","timestamp":1695570670000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.12891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":26,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1111\/imj.12891"],"URL":"https:\/\/doi.org\/10.1111\/imj.12891","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"2015-03-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-08-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}